USANA Health Sciences, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

COMMON STOCK AND EARNINGS PER SHARE

COMMON STOCK AND EARNINGS PER SHARE

9 Months Ended

Sep. 27, 2025

NOTE K – COMMON STOCK AND EARNINGS PER SHARE

Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised.

The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated:


	Three Months Ended				Nine Months Ended
	September 27, 2025		September 28, 2024		September 27, 2025		September 28, 2024
Net (loss) earnings attributable to USANA	$	(6,522)	$	10,607	$	12,535	$	37,576

Weighted average common shares outstanding - basic	18,293		19,078		18,618		19,108
Dilutive effect of in-the-money equity awards	—		5		53		73
Weighted average common shares outstanding - diluted	18,293		19,083		18,671		19,181
(Loss) earnings per common share from net (loss) earnings attributable to USANA:
Basic	$	(0.36)	$	0.56	$	0.67	$	1.97
Diluted	$	(0.36)	$	0.56	$	0.67	$	1.96

Equity awards excluded as the impact was anti-dilutive	368		628		410		570

Under the Company's share repurchase plan, there were no shares repurchased during the three months ended September 27, 2025 and September 28, 2024. During the nine months ended September 27, 2025 and September 28, 2024, the Company repurchased and retired 927 and 194 shares for $27,738 and $9,483, inclusive of accrued excise tax of $231 and $39, respectively.

The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

As of September 27, 2025, the remaining authorized repurchase amount under the stock repurchase plan was $33,965, inclusive of accrued excise tax. There is no expiration date on the remaining approved repurchase amount and no requirement for future share repurchases.